Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.

Cancer medicine - 1 Jan 2021

Sivapiragasam Abirami, Ashok Kumar Prashanth, Sokol Ethan S, Albacker Lee A, Killian Jonathan K, Ramkissoon Shakti H, Huang Richard S P, Severson Eric A, Brown Charlotte A, Danziger Natalie, McGregor Kimberly, Ross Jeffrey S

Abstract excerpt

We examined a large dataset of female metastatic breast cancers (MBCs) profiled with comprehensive genomic profiling (CGP) to identify the prevalence and distribution of immunotherapy responsiveness-associated biomarkers. DNA was extracted from 3831 consecutive MBCs: 1237 (ERpos /HER2neg ), 1953 ERneg /HER2amp , and 641 triple-negative breast cancer (TNBC). CGP was performed using the FoundationOne® or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Nucleic Acid

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Neoplasm Metastasis

Share to Precision Medicine

Share to Predictive Value of Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 33314633
DOI: 10.1002/cam4.3550
PMCID: PMC7826457

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.PMID 33314633Read ↗

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigmsSemantic proximity Read ↗

Assessment of blood-based tumor mutational burden on clinical outcomes in advanced breast and prostate cancer treated with immune checkpoint inhibitorsSemantic proximity Read ↗

High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities.Semantic proximity Read ↗

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.Semantic proximity Read ↗

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.Semantic proximity Read ↗

Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendationsSemantic proximity Read ↗

Breast cancer biomarkers and molecular medicine.Semantic proximity Read ↗

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.Semantic proximity Read ↗

The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.Semantic proximity Read ↗

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysisSemantic proximity Read ↗

The Multi-Omic Transformation of Breast Cancer Diagnostics: A Comprehensive Review of the Transition from Immunohistochemistry to Liquid Biopsy and Next-Generation SequencingSemantic proximity Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.